filter_events
On June 10, 2022, Senior Researcher of the Ukrainian Institute on Public Health Policy Tetiana Kiriazova became a special guest of InWomen's Conference - the first program event of CPDD 2022.
Dear friends and colleagues! First of all thank you for all your thoughts, prayers and support during these dark times. We continue to work and to do our best to support Ukraine and Ukrainian people.
We invite young painters to take part in a competition that will allow the younger generation to support all Ukrainians and especially the elderly in connection with today's realities - the war in Ukraine.
On April 13, 2022, the Head of the Board and Leading Researcher of UIPHP Sergii Dvoriak took part in a meeting of international experts in the field of public health, organized by Johns Hopkins Bloomberg School of Public Health (USA).
About 17,000 people in Ukraine rely on opioid agonist therapy. Chaotic wartime conditions endanger their treatment.
In a Global Health NOW exclusive, Head of the Board and Leading Researcher of UIPHP Sergii Dvoriak discussed working through supply and other challenges to help his team's study populations in dozens of hospitals, clinics, and medical centers across the country.
Buprenorphine was approved by the US Food and Drug Administration (FDA) in 2002 to treat opioid use disorder and pain.
The eleventh revision of the International Classification of Diseases, developed and annually updated by the World Health Organization, came into effect on 1 January 2022.